CPHI (China Pharma Holding) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

What is China Pharma Holding LT-Debt-to-Total-Asset?

China Pharma Holding CPHI -10.97% 26 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates CPHI with a GF Score™ of 26/100 and a GF Value™ of $0.24 (Significantly Overvalued). The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. China Pharma Holding's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

China Pharma Holding's long-term debt to total assets ratio declined from Mar. 2025 (0.10) to Mar. 2026 (0.00). It may suggest that China Pharma Holding is progressively becoming less dependent on debt to grow their business.

China Pharma Holding (AMEX:CPHI) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

China Pharma Holding LT-Debt-to-Total-Asset Related Terms

China Pharma Holding LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for China Pharma Holding's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Pharma Holding LT-Debt-to-Total-Asset Chart

China Pharma Holding Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.23

0.00

0.09

0.00

China Pharma Holding Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.10	0.10	0.01	0.00	0.00

26GF Score

China Pharma Holding Inc CPHI

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

China Pharma Holding LT-Debt-to-Total-Asset Calculation

China Pharma Holding's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	0.112	/	30.999
	=	0.00

China Pharma Holding's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0.092	/	45.144
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

China Pharma Holding (CPHI) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on China Pharma Holding and its competitors.

Is China Pharma Holding's LT-Debt-to-Total-Asset too high?

China Pharma Holding's current LT-Debt-to-Total-Asset is 0.00. Overall, China Pharma Holding has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does China Pharma Holding's LT-Debt-to-Total-Asset compare to TXMD and RMTI?

China Pharma Holding's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on China Pharma Holding and its competitors. China Pharma Holding's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is China Pharma Holding stock overvalued right now?

Based on GuruFocus' analysis, China Pharma Holding (CPHI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.24, compared to a current price of $0.57 — trading 137.5% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. China Pharma Holding's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For China Pharma Holding (CPHI), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Pharma Holding (CPHI) Overvalued in 2026?

Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued. The current stock price of $0.57 is trading 137.5% above its estimated GF Value™ of $0.24. GuruFocus considers China Pharma Holding to be Significantly Overvalued.

Key valuation signals for CPHI:

LT-Debt-to-Total-Asset: 0.00
GF Value™: $0.24 vs. price of $0.57 (137.5% above fair value)
GF Score™: 26/100 with 3 warning signs

No single metric tells the full story. See the CPHI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Pharma Holding Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TXMD RMTI AYTU MRMD HYEX ZYBT IGPK KAYS APUS BIOE XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Address No. 17, Jinpan Road, Second Floor, Jiahai Building, Hainan Province, Haikou, CHN, 570216

Website http://www.chinapharmaholdings.com

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.

26GF Score

Get the complete analysis for CPHI

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.57

Price

$0.24

GF Value

View CPHI Analysis

See LT-Debt-to-Total-Asset data for all stocks →